Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa

International Journal of Antimicrobial Agents

Volumn 21, Issue 5, 2003, Pages 409-413

  Higgins, P G ^a   Fluit, A C ^c   Milatovic, D ^c   Verhoef, J ^c   Schmitz, F J ^b,c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Efflux; Fluoroquinolone; GyrA; ParC; Pseudomonas aeruginosa

Indexed keywords

BACTERIAL PROTEIN; CIPROFLOXACIN; CLINAFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; GATIFLOXACIN; IMIPENEM; ISOLEUCINE; LEUCINE; LEVOFLOXACIN; MOXIFLOXACIN; PROTEIN MEXR; PROTEIN NFXB; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SERINE; SITAFLOXACIN; THREONINE; TROVAFLOXACIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REGULATOR GENE;

EID: 0037405379     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(03)00009-8     Document Type: Article

References (15)

1. Le Thomas I., Couetdic G., Clermont O., Brahimi N., Plesiat P., Bingen E. In vivo selection of a target/efflux double mutant of Pseudomonas aeruginosa by ciprofloxacin therapy. J. Antimicrob. Chemother. 48:2001;553-555.
2. Nakano M., Yasuda M., Yokoi S., Takahashi Y., Ishihara S., Deguchi T. In vivo selection of Pseudomonas aeruginosa with decreased susceptibilities to fluoroquinolones during fluoroquinolone treatment of urinary tract infection. Urology. 58:2001;125-128.
3. Jalal S., Ciofu O., Hoiby N., Gotoh N., Wretlind B. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob. Agents Chemother. 44:2000;710-712.
4. Ziha-Zarifi I., Llanes C., Kohler T., Pechere J.C., Plesiat P. In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM. Antimicrob. Agents Chemother. 43:1999;287-291.
5. Jalal S., Wretlind B. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa. Microb. Drug Resist. 4:1998;257-261.
6. Evans K., Adewoye L., Poole K. MexR repressor of the mexAB-oprM multidrug efflux operon of Pseudomonas aeruginosa: Identification of MexR binding sites in the mexA-mexR intergenic region. J. Bacteriol. 183:2001;807-812.
7. Brisse S., Milatovic S., Fluit A.C., et al. Molecular surveillance of European quinolone-resistant clinical isolates of Pseudomonas aeruginosa and Acinetobacter spp. using automated ribotyping. J. Clin. Microbiol. 38:2000;3636-3645.
8. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A5, 5th ed. Wayne, PA, NCCLS 2000.
9. Livermore D.M. Of Pseudomonas, porins, pumps and carbapenems. J. Antimicrob. Chemother. 47:2001;247-250.
10. Akasaka T., Tanaka M., Yamaguchi A., Sato K. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob. Agents. Chemother. 45:2001;2263-2268.
11. Mine T., Morita Y., Kataoka A., Mizushima T., Tsuchiya T. Expression in Escherichia coli of a new multidrug efflux pump, MexXY, from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 43:1999;415-417.
12. Kohler T., Micheahamzehpour M., Plesiat P., Kahr A.L., Pechere J.C. Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 41:1997;2540-2543.
13. Fukuda H., Hosaka M., Iyobe S., Gotoh N., Nishino T., Hirai K. nfxc-type quinolone resistance in a clinical isolate of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39:1995;790-792.
14. Okazaki T., Hirai K. Cloning and nucleotide-sequence of the Pseudomonas aeruginosa nfxB gene, conferring resistance to new quinolones. FEMS Microbiol. Lett. 97:1992;197-202.
15. Alekshun M.N., Levy S.B., Mealy T.R., Seaton B.A., Head J.F. The crystal structure of MarR, a regulator of multiple antibiotic resistance, at 2.3 angstrom resolution. Nat. Struct. Biol. 8:2001;710-714.